z-logo
open-access-imgOpen Access
Expression levels of matrix metalloproteinases in ascites of patients with ovarian cancer and the relationship with pathological characteristics of ovarian cancer
Author(s) -
S Shuna,
Ping Li,
Junfei Wang
Publication year - 2019
Publication title -
discussion of clinical cases
Language(s) - English
Resource type - Journals
eISSN - 2375-8449
pISSN - 2375-8473
DOI - 10.5430/dcc.v6n2p12
Subject(s) - ascites , ovarian cancer , pathological , medicine , matrix metalloproteinase , ovarian tumor , stage (stratigraphy) , gastroenterology , metastasis , pathology , lymph node , immunohistochemistry , cancer , biology , paleontology
Objective: To explore the expression levels of matrix metalloproteinase-2 (MMP-2) and matrix metalloproteinase-9 (MMP-9) in ascites in ovarian tumor and provide a theoretical basis for the diagnosis and prognosis evaluation of ovarian cancer ascites.Methods: ELISA was used to detect the levels of MMP-2 and MMP-9 in ascites samples from 73 cases of patients with malignant ovarian tumor, and RIA was used to detect the expression level of CA125 in the serum in these patients.Results: The expression levels of MMP-2 and MMP-9 in ascites in malignant ovarian tumor were higher than those in ascites in benign ovarian tumor (t = 8.08, 10.39, p .05). The sensitivities of detecting MMP-2 and MMP-9 in ascites were 76.0% and 88.0%, respectively, which were significantly higher than those of ascites cytological examinations (χ2 = 4.61, 12.74, p .05). The specificities of detecting MMP-2 and MMP-9 in ascites were 78.3% and 82.6%, respectively, which were significantly lower than those of ascites cytological examinations (χ2 = 5.61, 4.38, p < .05), but in comparison with serum CA125, there was no statistically significant difference (χ2 = 1.64, 2.68, p < .05).Conclusions: The levels of MMP-2 and MMP-9 in ascites may be markers for the differential diagnosis of benign and malignant ovarian lesions, and they are related to the prognosis in patients with malignant ovarian tumors.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here